adapalene + benzoyl peroxide + clindamycin

**Adapalene + benzoyl peroxide + clindamycin** is a fixed-dose topical triple-combination small-molecule acne therapy marketed as **Cabtreo** and developed by **Bausch Health** through **Ortho Dermatologics**. The gel contains clindamycin phosphate 1.2%, adapalene 0.15%, and benzoyl peroxide 3.1% and is indicated for topical treatment of acne vulgaris in adults and pediatric patients 12 years of age and older. Its components provide complementary mechanisms: adapalene is a topical retinoid that modulates retinoic acid receptors to normalize follicular keratinization and reduce comedone formation; benzoyl peroxide is an antimicrobial and keratolytic agent that reduces Cutibacterium acnes burden and helps limit emergence of antibiotic resistance; and clindamycin inhibits bacterial protein synthesis, reducing inflammatory acne lesions. The product is notable as the first and only FDA-approved fixed-dose triple-combination topical therapy for acne vulgaris and has been developed primarily for moderate-to-severe acne.

Brand names

Cabtreo

Other names

adapalene + benzoyl peroxide + clindamycinclindamycin phosphate + adapalene + benzoyl peroxide